Melatonin protects against 6-OHDA-induced neurotoxicity in rats: A role for mitochondrial complex I activity

FASEB Journal

Volumn 15, Issue 1, 2001, Pages 164-170

  Dabbeni Sala, F ^a   Di Santo, S ^a   Franceschini, D ^a   Skaper, S D ^a   Giusti, P ^a  

^a Department of Pharmacology ^*  (Italy)

Author keywords

Neurodegeneration; Neuroprotection; Oxidative phosphorylation; Parkinson's disease; Pineal hormone

Indexed keywords

MELATONIN; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; ENZYME ACTIVITY; LIPID PEROXIDATION; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX IV; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MALE; MELATONIN; MITOCHONDRIA; MOTOR ACTIVITY; NAD; NEUROPROTECTIVE AGENTS; OXIDATIVE PHOSPHORYLATION; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

ANIMALIA; PARKINSONIA;

EID: 0035170284     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0129com     Document Type: Article

References (69)

1. Etiology and pathogenesis of Parkinson'S disease
2. Oxidative stress, glutamate, and neurodegenerative disorders
3. Oxidative stress and antioxidant therapy in Parkinson'S disease
4. Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan)
5. On-off effects of dopamine receptor agonists in the hemi-Parkinsonian rat
6. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system
7. Turning behaviour in animals
8. Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior
9. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls
10. Reactive oxygen species influence nerve growth factor synthesis in primary rat astrocytes
11. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation
12. Oxidative stress and the pathogenesis of Parkinson'S disease
13. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases
14. Mitochondrial involvement in Parkinson'S disease, Huntington'S disease, hereditary spastic paraplegia and Friedreich'S ataxia
15. Human complex I defects in neurodegenerative diseases
16. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson'S disease
17. 6-Hydroxydopamine-mediated induction of rat brain metallothionein I mRNA
18. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: Involvement of the glutathione system
19. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-methyl-D-aspartate excitotoxicity
20. Neuroprotection by melatonin from kainate-induced excitotoxicity in rats
21. In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin
22. Melatonin maintains glutathione homeostasis in kainic acid-exposed rat brain tissues
23. Pharmacological actions of melatonin in oxygen radical pathophysiology
24. Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations
25. Melatonin: A peroxyl radical scavenger more effective than vitamin E
26. Melatonin protects neurons from singlet oxygen-induced apoptosis
27. Melatonin reduces kainate-induced lipid peroxidation in homogenates of different brain regions
28. Paraquat toxicity and oxidative damage. Reduction by melatonin
29. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: Implications for Parkinson'S disease
30. Determination of melatonin in rat pineal, plasma and retina by high-performance liquid chromatography with electrochemical detection
31. A rapid method for the regional dissection of the rat brain
32. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form
33. Quantification of muscle mitochondrial oxidative phosphorylation enzymes via histochemical staining of blue native polyacrylamide gels
34. Animal models of Parkinson'S disease: An empirical comparison with the phenomenology of the disease in man
35. Biochemical and imrnunochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: Evidence for cell death in the substantia nigra
36. On the effect of melatonin upon human brain. Its possible therapeutic implications
37. Melatonin and abnormal movements induced by L-DOPA in mice
38. Melatonin and parkinsonism
39. Melatonin and parkinsonism
40. A therapeutic role for melatonin antagonism in experimental models of Parkinson'S disease
41. Effects of daily melatonin injections on activity rhythms of rats in constant light
42. Free-running activity rhythms in the rat: Entrainment by melatonin
43. Melatonin modulates apomorphine-induced rotational behaviour
44. Mechanisms underlying the antidopaminergic effect of clouazepam and melatonin in serotonin
45. Oxygen free radicals, melatonin, and aging
46. New insights into the cause of Parkinson'S disease
47. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa
48. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
49. Dopamine neurotoxicity: Inhibition of mitochondrial respiration
50. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity
51. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson'S disease
52. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration
53. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson'S disease
54. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: A potential neuroprotective mechanism
55. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neuronsa possible novel pathogenetic mechanism
56. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain
57. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: Chemiluminescence and peroxidation
58. Free radicalgenerated neurotoxicity of 6-hydroxydopamine
59. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles
60. MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes
61. In vitro and in vivo neuroprotection with melatonin against toxicity of singlet oxygen
62. 2-induced lipid peroxidation in homogenates of different rat brain regions
63. Oxidative damage in the central nervous system: Protection by melatonin
64. Dally melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat
65. Melatonin is protective against MPTP-induced striatal and hippocampal lesions
66. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system
67. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications
68. Melatonin: Its intracellular and genomic actions